GlaxoSmithKline Pharmaceuticals Ltd. SWOT Analysis: Strengths, Weakness, Opportunity, and ThreatsGlaxoSmithKline Pharmaceuticals Ltd. SWOT Analysis: Strengths, Weakness, Opportunity, and Threats| Positive Breakout First Resistance ( LTP > R1) | |
| 30 Day SMA crossing over 200 Day SMA, and current price greater than open | 34.5% returns for Nifty 500 over 1.2 years |
| Brokers upgraded recommendation or target price in the past three months | 8.4% returns for Nifty 500 over 0.3 years |
| High Momentum Scores (Technical Scores greater than 50) | 319.5% returns for Nifty 500 over 5.1 years |
| Mutual Funds Increased Shareholding in Past Month | |
| Companies with high market cap, lower public shareholding | |
| Expensive Performers (DVM) | 550.5% returns for Nifty 500 over 10.2 years |
| High PE (PE > 40) | |
| Average Financial Performers - Stocks with Medium Trendlyne Durability Score versus Benchmarks | 187.6% returns for Nifty 500 over 4.5 years |
| Average Bullish Trend - Stocks with Medium Trendlyne Momentum Score versus Benchmarks | 181.7% returns for Nifty 500 over 4.5 years |
| Stocks with Expensive Valuations according to the Trendlyne Valuation Score | 177.2% returns for Nifty 500 over 4.5 years |
| Degrowth in Revenue, Profits and Operating Profit Margin in recent results (QoQ) | |
| Increasing Trend in Non-Core Income | |
| MFs increased their shareholding last quarter | |
| Top Gainers |